A practical reference on Melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
There were concerns in the 2000s about the sugar and vitamin content of Ribena, a blackcurrant-based syrup and soft drink owned by GSK until 2013. Produced in England by H.W. Carter & Co from the 1930s, the company's unbranded syrup was distributed to children as a source of vitamin C during World War II, which gave the drink a reputation as good for health. Beecham bought H. W. Carter in 1955. In 2001, the British Advertising Standards Authority (ASA) required GSK to withdraw its claim that Ribena Toothkind, a lower-sugar variety, did not encourage tooth decay. A company poster showed bottles of Toothkind in place of the bristles on a toothbrush. The ASA's ruling was upheld by the High Court. In 2007, GSK was fined US$217,000 in New Zealand over its claim that ready-to-drink Ribena contained high levels of vitamin C, after two schoolgirls showed it contained no detectable vitamin C. In 2013, GSK sold Ribena and another drink, Lucozade, to the Japanese multinational Suntory for £1.35 billion.
The mean percentage change in weight at week 72 was −15.0% (95% confidence interval [CI], −15.9 to −14.2) with 5-mg weekly doses of tirzepatide, −19.5% (95% CI, −20.4 to −18.5) with 10-mg doses, and −20.9% (95% CI, −21.8 to −19.9) with 15-mg doses. Weight change in the placebo group was −3.1% (95% CI, −4.3 to −1.9). The FDA approved tirzepatide based on evidence from nine clinical trials of 7,769 participants with type 2 diabetes, of whom 5,415 received tirzepatide. The trials were conducted at 673 sites in 24 countries, including Argentina, Australia, Brazil, Canada, India, Israel, Japan, Mexico, Russian Federation, South Korea, Taiwan, European Union, and the United States (including Puerto Rico). All nine trials were used to assess its safety, and five were used to evaluate its efficacy. The five used in efficacy evaluation included 6,263 adult participants with type 2 diabetes. Four additional trials (NCT03131687, NCT03311724, NCT03861052, and NCT03861039) were included in the safety evaluation, for a total of 7,769 adult participants with type 2 diabetes; therefore, the number of participants representing efficacy findings may differ from the number representing safety findings due to different pools of study participants analyzed for efficacy and safety. Tirzepatide's benefits for the treatment of adult participants with type 2 diabetes were primarily evaluated in five clinical trials. In two of these (NCT03954834 and NCT04039503), participants were randomly assigned to receive either tirzepatide or placebo injection weekly.
=== Procedure (Micro Assay, 1-10 μg protein/mL) === Prepare standard concentrations of protein of 1, 5, 7.5 and 10 μg/mL. Prepare a blank of NaCl only. Prepare a series of sample dilutions. Add 100 μL of each of the above to separate tubes (use microcentrifuge tubes) and add 1.0 mL of Coomassie Blue to each tube. Turn on and adjust a spectrophotometer to a wavelength of 595 nm, and blank the spectrophotometer using 1.5 mL cuvettes or use a mobile smartphone camera (RGBradford method). Wait 2 minutes and read the absorbance of each standard and sample at 595 nm. Plot the absorbance of the standards vs. their concentration. Compute the extinction coefficient and calculate the concentrations of the unknown samples.
The nephritic syndrome is characterised by blood in the urine (especially Red blood cell casts with dysmorphic red blood cells) and a decrease in the amount of urine in the presence of hypertension. In this syndrome, inflammatory damage to cells lining the glomerulus are thought to result in destruction of the epithelial barrier, leading to blood being found in the urine. At the same time, reactive changes, e.g. proliferation of mesangial cells, may result in a decrease in kidney blood flow, resulting in a decrease in the production of urine. The renin–angiotensin system may be subsequently activated, because of the decrease in perfusion of juxtaglomerular apparatus, which may result in hypertension.
== History == The group began as a jangly indie pop band influenced by Primal Scream's early sound. By the time they recorded their first EP, Barging Into the Presence of God, released in 1989, the band went into a direction that displayed a mix of Ian Masters' ethereal, choirboy-like vocals along with dark atmospheric and noisy pop tunes. Ashley Horner from Edsel Auctioneer briefly joined the band on guitar in the same year. The band was signed to 4AD Records after their first London show by the label's chief Ivo Watts-Russell. The group's first album, The Comforts of Madness, was released in 1990 and reached the top 40 of the UK Albums Chart. The album's tracks were produced by John Fryer and Gil Norton. The album includes a cover version of "Fell from the Sun" by Opal. In late 1990, Meriel Barham, the original vocalist of Lush, joined the band as second guitarist and vocalist. Barham contributed backing vocals and guitars to the Chris Allison produced Half-Life EP, then joined permanently for the Nancy Sinatra cover "Kinky Love", which gave the band a minor hit single as part of Flesh Balloon EP. In 1992 the band recorded their second full-length album, In Ribbons, which was produced by Hugh Jones. Ian Masters left the band in 1993, citing his lack of enthusiasm for touring, unlike the remaining members of the band and their record label 4AD. Former Heart Throbs bassist Colleen Browne joined afterwards. Sticking with producer Hugh Jones, the group released the Fine Friend EP in mid-1994, followed by their third album, Slow Buildings.
Sources: en.wikipedia.org
Currently approved CCEEVs are also more thermotolerant than the label suggests: a commercial CCEEV packaged as a ready-to-inject solution in a vial, with a 2–8 °C recommendation from the manufacturer, was found to have lost none of its effectiveness in dogs after spending three months at 30 °C (86 °F). It is believed that liquid vaccines degrade by processes such as aggregation of protein particles, so dry human vaccines are expected to be even more stable. Indeed, a human CCEEV was found to remain effective after three months at 37 °C (99 °F).
Zhang's tactics included propaganda, intelligence-gathering, and involvement in the opium trade, while Liu fought back with counter-propaganda and appointing loyalist magistrates who frustrated Zhang's work. Liu triumphed in 1942 when the 36th Division was moved to the Yunnanese front, and Zhang was transferred back to Chongqing in 1946. Zhang's presence was replaced by He Guoguang, but Liu continued frustrating Nationalist centralization attempts. In 1944 during Operation Ichi-Go, there was once again talk of moving the capital to Xichang, encouraged by American General Wedermeyer, but this was abandoned after the Japanese offensive stalled. In late 1942, Chiang ordered Liu and Ma Bufang of Qinghai to mobilize for a campaign against Tibet. Liu was suspicious of the Nationalist leader's motivations, dispatching his chief of staff Wu Peiying (伍培英) to Chongqing to plan for the invasion and negotiate with Chiang. According to Liu's 1990 biography, he had asked for a fully-equipped division of 10,000 troops, cavalry, and engineers; another division to maintain order, winter equipment, around 10,000 yaks, additional food supplies, and a truck route from Sichuan to Xikang. Liu also requested that he take sole command of these reinforcements. Later archival documents would confirm Liu's suspicions that the campaign was a plot; once Liu had mobilized his forces, Chiang was to send 30,000 men under his personal command into Xikang and depose Liu. Due to Liu's stalling tactics as well as Allied pressure, the campaign did not materialize.
== Economics == Clinical trial costs vary depending on trial phase, type of trial, and disease studied. A study of clinical trials conducted in the United States from 2004 to 2012 found the average cost of phase I trials to be between $1.4 million and $6.6 million, depending on the type of disease. Phase II trials ranged from $7 million to $20 million, and phase III trials from $11 million to $53 million.
PF-04455242 is an experimental κ-opioid receptor (KOR) antagonist which was under development by Pfizer for the treatment of bipolar depression but was never marketed. Its development was discontinued in early clinical trials. It is taken by mouth.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.